RenovoRx, Inc. (RNXT) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, RenovoRx, Inc.'s filing signal continuing negative.

RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies, notably its Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform, which utilizes the FDA-cleared RenovoCath(R) device for intra-arterial drug delivery. The company is actively commercializing RenovoCath as a standalone device in the U.S., having generated $1.1 million in revenue in 2025 from sales to cancer centers. RenovoRx is also advancing its lead drug-device combination product candidate, IAG (intra-arterial gemcitabine delivered via RenovoCath), through a Phase III clinical trial for locally advanced pancreatic cancer (LAPC). The TAMP platform aims to enhance drug concentration at the tumor site while minimizing systemic toxicities compared to intravenous therapy. RenovoCath has received FDA 510(k) clearance for various applications, including chemotherapeutic drug infusion.

Revenue is primarily driven by the commercial sales of the RenovoCath device as a standalone product to U.S. cancer centers. The company also anticipates future revenue from its IAG drug-device combination product candidate, pending regulatory approval.